The Impact of Transvenous Cardiac Devices on Vascular Access Patency in Hemodialysis Patients

Cardiac implantable electronic devices in end-stage renal disease patients: preservation of central venous circulation

(2012) Gustavo Lopera et al.   JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY

Trends in the Use and Outcomes of Implantable Cardioverter-Defibrillators in Patients Undergoing Dialysis in the United States

(2011) David M. Charytan et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Transvenous Cardiac Device Wires and Vascular Access in Hemodialysis Patients

(2011) David A. Drew et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

End-Stage Renal Disease Predicts Complications in Pacemaker and ICD Implants

(2011) CHRISTINE TOMPKINS et al.   JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY

The dilemma of transvenous cardiac rhythm devices in hemodialysis patients: time to consider the epicardial approach?

(2011) Arif Asif et al.   KIDNEY INTERNATIONAL

Implantable Defibrillators Improve Survival in End-Stage Renal Disease: Results from a Multi-Center Registry

(2010) Swapnil Hiremath et al.   AMERICAN JOURNAL OF NEPHROLOGY

An Entirely Subcutaneous Implantable Cardioverter–Defibrillator

(2010) Gust H. Bardy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epicardial Cardiac Rhythm Devices for Dialysis Patients: Minimizing the Risk of Infection and Preserving Central Veins

(2010) Arif Asif et al.   SEMINARS IN DIALYSIS

Meta-Analysis of Mortality in Dialysis Patients With an Implantable Cardioverter Defibrillator††Disclosures: Dr. Bhatt has received research grants (directly to the institution) from Bristol-Myers Squibb, New York, New York; Eisai Inc., Woodcliff Lake, New Jersey; Ethicon, Inc., Somerville, New Jersey; Heartscape Technologies, Inc., Columbia, Maryland; Sanofi-Aventis, Paris, France; and The Medicines Company, Parsippany, New Jersey. Dr. Bhatt is a consultant for or member of the advisory boards (honoraria waived or donated to nonprofit organizations) of Arena Pharmaceuticals, Inc., San Diego, California; AstraZeneca PLC, London, United Kingdom; Bristol-Myers Squibb; Cardax Pharmaceuticals, Inc., Aiea, Hawaii; Centocor, Inc., Horsham, Pennsylvania; Cogentus Pharmaceuticals, Palo Alto, California; Daiichi Sankyo, Inc., Parsippany, New Jersey; Eisai Inc.; Eli Lilly and Company, Indianapolis, Indiana; GlaxoSmithKline PLC, London, United Kingdom; Johnson & Johnson, New Brunswick, New Jersey; Ortho-McNeil, Raritan, New Jersey; Medtronic, Inc., Minneapolis, Minnesota; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; Otsuka Pharmaceutical Company, Ltd., Tokyo, Japan; ParinGenix, Inc., Weston, Florida; PDL BioPharma, Inc., Redwood City, California; Philips Medical Systems, Andover, Massachusetts; Portola Pharmaceuticals Inc., South San Francisco, California; Sanofi-Aventis; Schering-Plough Corporation, Kenilworth, New Jersey; The Medicines Company; and Vertex Pharmaceuticals, Inc., Cambridge, Massachusetts.

(2009) Rahul Sakhuja et al.   AMERICAN JOURNAL OF CARDIOLOGY

Implantable cardioverter defibrillator therapy in chronic kidney disease: a meta-analysis

(2009) P. Korantzopoulos et al.   EUROPACE

Permanent pacemaker implantation technique: part I

(2009) K. Rajappan   HEART

Informatics in Radiology

(2009) Pragya A. Dang et al.   RADIOGRAPHICS

Patency Rates for Angioplasty in the Treatment of Pacemaker-Induced Central Venous Stenosis in Hemodialysis Patients: Results of a Multi-Center Study

(2009) Arif Asif et al.   SEMINARS IN DIALYSIS

HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations

(2008) Bruce L. Wilkoff et al.   HEART RHYTHM